Combination topical 5-fluorouracil 5%/calcipotriene 0.005% cream for the treatment of cutaneous in situ squamous cell carcinoma: a pilot study of efficacy and risks

Published: 15 March 2024| Version 1 | DOI: 10.17632/6jy5wckfyz.1
Contributors:
Riya Patel, Kiley Fagan, Eugenie Quan, Joshua Eikenberg, Mariana Phillips

Description

Background: Various treatment options, including surgical excision and non-invasive modalities, exist for managing squamous cell carcinoma in situ (SCCIS). This pilot study investigated the safety and efficacy of a compounded 5-FU 5%/calcipotriene 0.005% cream in the treatment of SCCIS in this single-center, single-blinded, randomized study. Methods: Patients were randomized into one of three groups: a placebo group, a 7-day application group, or a 14-day application group. All patients received surgical excision at least 20 days after completion of cream application. Results: Significant differences in histological clearance of SCCIS between the treatment and control groups were identified (p<0.001). There was a complete histological clearance in 83.3% and 87.5% of patients in the 7- and 14-day treatment groups, respectively. All patients in the placebo group showed residual tumor on histological evaluation. Adverse effects, including redness, itching, and burning, were more commonly reported in the 14-day treatment group. Two patients in the treatment groups developed reactive squamous proliferations within the scar approximately 61-96 days after excision. Conclusion: Topical 5-fluorouracil 5%/calcipotriene 0.005% cream is effective in inducing histological clearance of SCCIS when applied twice daily for 7 or 14 days. Reactive squamous atypia may occur in surgical scars if excision is performed within 35 days of cream application.

Files

Institutions

Carilion Clinic, Virginia Tech Carilion School of Medicine

Categories

Dermatology, Squamous Cell Carcinoma, 5-Fluorouracil

Funding

Carilion Clinic

Licence